Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine
- PMID: 27189148
- DOI: 10.1007/s12020-016-0989-3
Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine
Abstract
The purpose of this study was to determine the natural temporal trends of serial thyroglobulin (Tg) among low/intermediate-risk PTC patients not receiving radioactive iodine (RAI) using TSH-stimulated Tg (Stim-Tg) and unstimulated highly sensitive Tg (u-hsTg). We prospectively analyzed serial Stim-Tg measurements after total thyroidectomy ± therapeutic central neck dissection among 121 consecutive low/intermediate-risk PTC patients who did not receive RAI, of whom 104 also had serial u-hsTg measurements available. Median follow-up was 6.5 years with Stim-Tg measurements commencing 3 months after surgery and u-hsTg commencing 1.8 years after surgery (when the assay became available). TSH stimulation was performed with 9-day T3 withdrawal, 22-day T4 withdrawal, or using recombinant human TSH (rhTSH). To account for within-patient correlations of repeated Tg measurements, temporal trends in Stim-Tg and u-hsTg were assessed using Generalized Estimating Equations. Stim-Tg models were adjusted for the method of TSH stimulation, whereas the u-hsTg models were adjusted for concurrent TSH level. Linear regression modeling was used to assess the trend in serial Stim-Tg and u-hsTg measurements as a function time from time of surgery throughout the duration of follow-up. The main outcome measured was the change in u-hsTg and Stim-Tg measurements over time. A total of 337 Stim-Tg (2.8/patient) and 602 u-hsTg (5.8/patient) measurements were analyzed. Among the 337 Stim-Tg measurements, Stim-Tg was assessed using rhTSH in 202 (60 %), T4 withdrawal in 41 (12 %), and T3 withdrawal in 94 (28 %) measurements. The overall mean ± 1SD for Stim-Tg and u-hsTg measured was 1.0 ± 1.2 and 0.2 ± 0.1 μg/L, respectively. When adjusted for method of TSH stimulation, serial Stim-Tg measurements did not significantly change over time (all p = NS). The estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were 0.01, -0.08, and 0.04 μg/L, respectively. Upon exclusion of 73 patients with an initial undetectable Stim-Tg (n = 48), serial Stim-Tg measurements did not change significantly over time (all p = NS). For these patients, the estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were -0.09, -0.10, and 0.01 μg/L, respectively. Serial u-hsTg measurements did not significantly change over time after adjusting for TSH level (p = NS). The estimated change in u-hsTg per year was -0.003 μg/L. No patients had any clinical or imaging evidence of a recurrence during the duration of their follow-up. Among low/intermediate-risk PTC patients not treated with RAI, serial post-surgical Stim-Tg and u-hsTg measurements do not change significantly over a median follow-up of 6.5 years.
Keywords: Papillary thyroid cancer; Post-surgical; Stimulated thyroglobulin; Thyroglobulin; Unstimulated highly sensitive thyroglobulin.
Similar articles
-
Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.Endocrine. 2015 Sep;50(1):130-7. doi: 10.1007/s12020-015-0575-0. Epub 2015 Mar 20. Endocrine. 2015. PMID: 25792004
-
Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.J Endocrinol Invest. 2003 Oct;26(10):1023-31. doi: 10.1007/BF03348202. J Endocrinol Invest. 2003. PMID: 14759077
-
Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?Thyroid. 2010 Jan;20(1):15-23. doi: 10.1089/thy.2008.0416. Thyroid. 2010. PMID: 20017617
-
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.J Clin Endocrinol Metab. 2003 Apr;88(4):1433-41. doi: 10.1210/jc.2002-021702. J Clin Endocrinol Metab. 2003. PMID: 12679418 Review.
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
Cited by
-
Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer.Endocr Connect. 2023 Jan 24;12(2):e220312. doi: 10.1530/EC-22-0312. Print 2023 Feb 1. Endocr Connect. 2023. PMID: 36507775 Free PMC article.
-
Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?Surgery. 2018 Jan;163(1):118-123. doi: 10.1016/j.surg.2017.05.028. Epub 2017 Nov 8. Surgery. 2018. PMID: 29128176 Free PMC article.
-
Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.Endocrine. 2020 Feb;67(2):387-396. doi: 10.1007/s12020-019-02112-7. Epub 2019 Oct 24. Endocrine. 2020. PMID: 31650394
-
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.Endocr Rev. 2017 Aug 1;38(4):351-378. doi: 10.1210/er.2017-00067. Endocr Rev. 2017. PMID: 28633444 Free PMC article. Review.
-
Strategies for Radioiodine Treatment: What's New.Cancers (Basel). 2022 Aug 4;14(15):3800. doi: 10.3390/cancers14153800. Cancers (Basel). 2022. PMID: 35954463 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous